0 186

Cited 0 times in

p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoraiotherapy for advanced rectal cancer

 Nam Kyu Kim  ;  Jae Kun Park  ;  Kang Yong Lee  ;  Woo IK Yang  ;  Seong Hyeon Yun  ;  JinSil Sung  ;  Jin Sik Min 
 ANNALS OF SURGICAL ONCOLOGY, Vol.8(5) : 418-424, 2001 
Journal Title
Issue Date
Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology* ; Adenocarcinoma/radiotherapy ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Humans ; Immunohistochemistry ; Ki-67 Antigen/analysis* ; Prognosis ; Proto-Oncogene Proteins c-bcl-2/analysis* ; Tumor Suppressor Protein p53/analysis*
rectal cancer ; preoperative chemoradiotherapy ; tumor response ; p53 ; BCL-2 ; Ki-67
BACKGROUND: Concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer is an important modality for curative resection, but tumors show wide spectrum response. The purpose of this study was to investigate any correlation among related genetic mutations, proliferative index, and tumor response after CCRT. METHODS: This study included 23 patients with rectal cancer, who were preoperatively staged as at least T3 N1 or T4 (determined by transrectal ultrasonography and MRI). Enrolled patients were given 5-FU 450 mg/m2/day and leucovorin 20 mg/m2/day intravenously for 5 days during weeks 1 and 5 of radiotherapy (45-54 Gy). Surgical resection was performed 4 weeks after completion of the scheduled treatment. Tumor response was classified as CR (complete response), PR (partial response: 50% diminution of tumor volume and downstaging), and NR (no response). Paraffin-embedded tissue obtained before chemoradiotherapy was studied by immunohistochemical staining for p53, BCL-2, and Ki-67. The extent of tumor response was correlated with proliferative activity and was measured by immunostaining Ki-67 proliferative antigen and the expression of p53 and BCL-2 oncoproteins. RESULTS: All patients were resectable. CR was obtained in 4 patients, PR in 10 patients, and NR in 9 patients. The p53 mutation was noted in 16 patients: NR in 5 patients, PR in 9 patients, and CR in 2 patients (P = .638). BCL-2 expression was noted in 11 patients: NR in 4 patients, PR in 3 patients, and CR in 4 patients (P = .799). The Ki-67 labeling index was NR: 615.4+/-47.2; PR: 663.2+/-20.4; and CR: 765.5+/-58.3 (CR + PR vs. NR, P = .029). CONCLUSIONS: Immunohistochemical expression of p53 and BCL-2 does not correlate with tumor response after CCRT, but Ki-67 labeling may be a useful parameter for radiosensitive tumors selected for CCRT.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Kang Young(이강영)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.